Asha Therapeutics is happy to announce the appointment of Dr. Craig Blackstone as a member of its Board of Administrators and as Chair of the Scientific Advisory Board.
Asha Therapeutics (Asha) is a neuro-centric biotechnology firm which focuses solely on de novo drug discovery and chemical design, leveraging the power of its disruptive PRISM™ know-how platform to develop novel therapeutics for neurological illnesses with excessive unmet medical want.
Every compound in Asha Therapeutics’ pipeline is designed to revive mobile well being at a pivotal juncture of neuronal downturn. This has resulted in a sturdy, holistic asset portfolio that treats neurological illness by contemplating neuronal deterioration and loss from a number of vantage factors. Inside Asha’s pipeline, lead asset ASHA-091 is a close to clinic-ready, custom-designed, mind penetrant compound that restores the mitochondrial community, selling cell survival over cell loss of life in numerous neurological situations.
Sam Shrivastava, Asha’s Founder and CEO, famous, “Dr. Blackstone is a worldwide thought chief and extremely completed doctor and clinician dedicated to cutting-edge scientific innovation with the potential to remodel affected person outcomes. Dr. Blackstone’s management driving pioneering scientific inquiry within the space of neurodegenerative illnesses, for which current therapeutics largely handle the mitigation of signs quite than arrest the supply of the illness itself, might be invaluable as Asha develops its pipeline with lead belongings demonstrating strong preclinical efficacy and security in lead indications and extra fashions of neurological dysfunction together with Parkinson’s Illness, Alzheimer’s Illness, Ischemic Stroke, and ALS.”
Reflecting on his new place at Asha Therapeutics, Dr. Blackstone commented, “I’m privileged to hitch the Board of Administrators of Asha Therapeutics and sit up for working with their cohesive and extremely progressive crew. I’ve been very impressed with Asha’s means to quickly develop a number of, extremely important compounds utilizing their proprietary physics-based and AI-driven PRISM™ platform. These belongings are poised to enter medical research quickly, offering desperately wanted new first-in-class therapies and hope for many individuals with devastating neurodegenerative and oncologic issues.”
Dr. Craig Blackstone is Chief of the Motion Issues Division on the Massachusetts Common Hospital and Professor of Neurology at Harvard Medical Faculty. He obtained B.S./M.S. levels from the College of Chicago and M.D./Ph.D. levels from Johns Hopkins. After neurology residency within the Harvard-Longwood Neurology Program, Dr. Blackstone pursued medical fellowship coaching in motion issues at Massachusetts Common Hospital and postdoctoral analysis coaching in neurobiology with Dr. Morgan Sheng at Harvard Medical Faculty and the Howard Hughes Medical Institute. In 2001, Dr. Blackstone joined the NINDS, the place he remained for twenty years, rising to Senior Investigator and Cell Biology Part Chief. His group investigated the mobile and molecular mechanisms underlying hereditary motion issues. He’s an elected member of the American Society for Medical Investigation, Affiliation of American Physicians, and Nationwide Academy of Medication in addition to an elected Fellow and former Vice President of the American Neurological Affiliation (ANA). He has held quite a few different management positions within the ANA, together with on its Govt Council, Schooling Innovation Committee, Nominations Committee, and Skilled Improvement Committee, in addition to Director of its Translational and Medical Analysis Course and Chair of its Internet Governance Committee. Dr. Blackstone at the moment serves on the editorial board of the Journal of Medical Investigation. He obtained the NIH Director’s Ruth L. Kirschstein Mentoring Award in 2012 and the NINDS Director’s Variety Achievement Award in 2018.